Cell Growth Promoter and Application thereof

US2025019646A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2025019646-A1
Application numberUS-202418668297-A
CountryUS
Kind codeA1
Filing dateMay 20, 2024
Priority dateJul 12, 2023
Publication dateJan 16, 2025
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A cell growth promoter and an application thereof are provided. The invention adopts Fe 2+ and ovalbumin to form a Fe 2+ -ovalbumin (OVA) compound to promote ovalbumin cell endocytosis, the cell growth promoter can maintain cell growth in an environment free of amino acids, promote cell proliferation in an environment with amino acids; and, the Fe 2+ -OVA compound can replace expensive animal serum albumin in cell culture, the cell growth promoter has a significant effect on improving cell viability and is low cost.

First claim

Opening claim text (preview).

What is claimed is: 1 . A cell culture medium, comprising a Fe 2+ -ovalbumin (OVA) compound, wherein a concentration of the Fe 2+ -OVA compound in the cell culture medium is 1 μg/mL-1000 μg/mL; the cell culture medium does not contain an amino acid; and the cell culture medium does not contain an animal serum albumin. 2 . A cell culture method, comprising culturing cells in the cell culture medium according to claim 1 . 3 . A method for improving a cell viability, comprising adding a Fe 2+ -OVA compound, wherein a final concentration of Fe 2+ added is 10-100 μM, and a final concentration of OVA added is 10-100 μM; and a cell is a mammalian cell, and the method is for non-diagnostic or non-therapeutic purposes. 4 . The method for improving the cell viability according to claim 3 , wherein the method is performed in an environment being free of an amino acid or deficient in the amino acid. 5 . The method for improving the cell viability according to claim 3 , wherein in the method, an animal serum albumin is replaced with the Fe 2+ -OVA compound.

Assignees

Inventors

Classifications

  • Proteins not provided for elsewhere · CPC title

  • Serum-free medium, which may still contain naturally-sourced components · CPC title

  • Iron; Fe chelators; Transferrin · CPC title

  • Amino acids, peptides or proteins · CPC title

  • Calcium; Ca chelators; Calcitonin · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2025019646A1 cover?
A cell growth promoter and an application thereof are provided. The invention adopts Fe 2+ and ovalbumin to form a Fe 2+ -ovalbumin (OVA) compound to promote ovalbumin cell endocytosis, the cell growth promoter can maintain cell growth in an environment free of amino acids, promote cell proliferation in an environment with amino acids; and, the Fe 2+ -OVA compound can replace expensive animal …
Who is the assignee on this patent?
Univ China Agricultural
What technology area does this patent fall under?
Primary CPC classification C12N5/0037. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Jan 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).